首页> 美国卫生研究院文献>Case Reports in Oncological Medicine >Durable Clinical Benefit of Pertuzumab in a Young Patient with BRCA2 Mutation and HER2-Overexpressing Breast Cancer Involving the Brain

【2h】

Durable Clinical Benefit of Pertuzumab in a Young Patient with BRCA2 Mutation and HER2-Overexpressing Breast Cancer Involving the Brain

机译：帕妥珠单抗在患有BRCA2突变和HER2过表达的涉及大脑的乳腺癌的年轻患者中的持久临床益处

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Patients with HER2-positive breast cancer and brain metastases have limited treatment options, and, as a result of their poor performance status and worse prognosis, they are underrepresented in clinical trials. Not surprisingly, these patients may not be fit enough to receive any active treatment and are offered supportive therapy. BRCA2 mutations are reported to be rarely associated with HER2-overexpressing advanced breast cancer and even more rarely with brain metastases at diagnosis. We report on a BRCA2-positive breast cancer patient with metastatic disease in multiple sites, including the brain, and poor performance status who exhibited an extraordinary clinical and imaging response to the novel anti-HER2 therapy pertuzumab after multiple lines of therapy including anti-HER2 targeting. To our knowledge, the clinicopathologic and therapeutic characteristics of this patient point to a unique case and an urgent need for further investigation of pertuzumab in patients with brain metastases.

机译：患有HER2阳性乳腺癌和脑转移的患者的治疗选择有限，并且由于他们的低下状态和预后较差，因此在临床试验中代表性不足。毫不奇怪，这些患者可能不适合接受任何积极的治疗，无法获得支持治疗。据报道，BRCA2突变很少与过表达HER2的晚期乳腺癌相关，在诊断时甚至很少与脑转移有关。我们报道了一位BRCA2阳性乳腺癌患者，该患者在包括大脑在内的多个部位都有转移性疾病，并且表现欠佳，在经过包括抗HER2在内的多种治疗后，对新型抗HER2治疗的帕妥珠单抗表现出非凡的临床和影像学反应定位。据我们所知，该患者的临床病理和治疗特征表明其为独特病例，迫切需要对脑转移患者中的帕妥珠单抗进行进一步研究。

著录项

期刊名称 Case Reports in Oncological Medicine
作者
Anna Koumarianou; Christina Kontopoulou; Vassilis Kouloulias; Christina Tsionou;
展开▼
作者单位

展开▼
年(卷),期 2016(2016),-1
年度 2016
页码 5718104
总页数 5
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. BRCA1 and BRCA2 mutations in Turkish breast/ovarian families and young breast cancer patients [J] . H Yazici, O Bitisik, E Akisik, British Journal of Cancer . 2000,第6期

机译：土耳其乳腺癌/卵巢家族和年轻乳腺癌患者的BRCA1和BRCA2突变
2. Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age [J] . Drooger Jan C., Akdeniz Delal, Pignol Jean-Philippe, Breast cancer research and treatment. . 2015,第1期

机译：BRCA1和BRCA2突变携带者对原发性乳腺癌的辅助放疗和对侧乳腺癌的风险，尤其要注意年轻时接受放射治疗的患者
3. Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age [J] . Drooger Jan C., Akdeniz Delal, Pignol Jean-Philippe, Breast cancer research and treatment. . 2015,第1期

机译：BRCA1和BRCA2突变携带者的辅助放疗和BRCA2突变携带者的风险和对侧乳腺癌的风险，特别注意患者患者较年轻的患者
4. Which Patients may benefit from the Use of a Decision Support System to Improve Compliance of Physician Decisions with Clinical Practice Guidelines: A Case Study with Breast Cancer involving Data Mining [C] . Brigitte Seroussi, Arnaud Soulet, Jean-Philippe Spano, MEDINFO . 2013

机译：哪些患者可以从使用决策支持系统中受益，以改善与临床实践指南的医生决策的遵守情况：涉及数据挖掘的乳腺癌案例研究
5. Mutation profiling in colorectal cancer patients with microsatellite instability; High frequency of BRCA2 and EGFR somatic mutations [D] . Deihimi, Safoora. 2016

机译：具有微卫星不稳定性的大肠癌患者的突变谱； BRCA2和EGFR体细胞突变的频率高
6. Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients [O] . Y H Park, M J Park, S H Ji, 2009

机译：曲妥珠单抗治疗可通过控制和持久延长过度表达HER2的乳腺癌患者的系统性颅外疾病来改善脑转移结果
7. Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients [O] . Park, Y H, Park, M J, Ji, S H, 2009

机译：曲妥珠单抗治疗可通过控制和持久延长过度表达HER2的乳腺癌患者的全身颅外疾病来改善脑转移结果

Durable Clinical Benefit of Pertuzumab in a Young Patient with BRCA2 Mutation and HER2-Overexpressing Breast Cancer Involving the Brain

摘要

著录项

相似文献

相关主题

期刊订阅